Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy.
ABSTRACT To evaluate whether serum levels of the soluble form of CD30 (sCD30) correlate with disease activity in early rheumatoid arthritis (RA) and may have prognostic value in predicting the response to disease-modifying anti-rheumatic drugs (DMARDs).
The levels of sCD30 and C-reactive protein (CRP) were measured in the serum of 14 untreated subjects with early RA, before and during treatment with hydroxychloroquine, for a follow-up period of 8 months. At the end of the study, patients were also evaluated for their response to DMARDs.
An inverse correlation between sCD30 and CRP serum values was demonstrated at baseline, but not during the follow-up. Patients who responded to DMARD therapy had higher sCD30 basal levels than non-responders.
The evaluation of sCD30 serum levels in early RA may reflect the attempt by CD30+ T cells to downmodulate inflammation and may be a useful marker to predict a good response to DMARDs.
[Show abstract] [Hide abstract]
ABSTRACT: CD30 and CD30 ligand (CD30L) are members of TNF-receptor and TNF superfamilies respectively. CD30(+)T cells are increased in several diseases and interaction between CD30(+) and CD30L(+)T cells leads either to cell proliferation or apoptosis. In patients with rheumatoid arthritis (RA), soluble CD30 (sCD30) levels seem to reflect the recruitment of CD30(+)T cells into the inflamed joints and are predictive of a positive response to classical and biological immunosuppressive therapy. We have evaluated the presence of soluble CD30L (sCD30L) in the sera and synovial fluid of patients with RA and defined whether it binds surface CD30 molecule and is functionally active. We found high levels of sCD30L in sera and synovial fluid of RA patients; the molecule is shedded upon direct contact of CD30(+)/CD30L(+)T cells. Moreover sCD30L binds surface CD30 constitutively expressed by Jurkat cell line. Finally recombinant sCD30L and sera from patients with high levels of sCD30L are able to inhibit CD30(+)T cell proliferation by inducing cell apoptosis. Our findings suggest that circulant sCD30L is functionally active and that it may favour persistence of active inflammation by inducing apoptosis of CD30(+)T cells, known to down-modulate inflammation in rheumatoid synovitis.Immunology letters 01/2014; DOI:10.1016/j.imlet.2014.01.007 · 2.37 Impact Factor
Revue du Rhumatisme 12/2010; 77(6):590-595. DOI:10.1016/j.rhum.2010.05.011
[Show abstract] [Hide abstract]
ABSTRACT: Materials and Methods: lymphocytes of 10 pa-tients having early rheumatoid arthritis (RA) (the duration of the illness was 3 -6 months) with a marked exudational process in joints were ex-amined. The content of lymphocytes expressing the mIgM, mIgG antigens was determined. Results: the "Taban-Arshan" extract corrects the changes of the immune system character-ized by the evident activation of the B-cell part of the immune system and normalizes immune parameters of the lymphocytes taken from the patients with autoimmune diseases (early rheumatoid arthritis). The immunocorrective effect of the "Taban-Arshan" extract is related to its ability to suppress the lymphocyte increased activation by normalizing expression of the main activation antigens (CD23, CD25, CD71, HLA-DR, CD54).